Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.[citation needed]
Company type | Privately held company |
---|---|
Industry | research and development in biotechnology |
Founded | Marseille, France (1999 ) |
Founder |
|
Defunct | 2015 |
Fate | Acquired by Hoffmann-La Roche |
Headquarters | France |
Trophos was founded in 1999 in Marseille by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622),[1][2] a mitochondrial targeted compound developed to treat neurodegenerative diseases.[3][4]
In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for €120,000,000 upfront and up to €350,000,000 in milestone performance payments.[5][6] The deal was completed shortly afterwards.